From the Albert Einstein College of Medicine, Bronx, NY (EO, AP-C, LR, MG, ADF); Montefiore Medical Center, Bronx, NY (AP-C, LR, MG, ADF); The City College of New York, New York, NY (TL-C).
J Addict Med. 2023;17(3):e148-e155. doi: 10.1097/ADM.0000000000001093. Epub 2022 Oct 16.
Injectable opioid agonist treatment (iOAT) is a novel approach to treating opioid use disorder (OUD) that is typically reserved for treatment-experienced persons who inject drugs (PWID) with long-standing OUD. This study examined PWID's past OUD treatment histories and their attitudes toward iOAT with hydromorphone.
This cross-sectional study recruited syringe services program participants with OUD in New York City. Participants self-reported past OUD care episodes (detoxification; outpatient, inpatient, or medication treatment; or mutual aid groups) and current interest in iOAT with hydromorphone (assessed on a 4-point scale with 3 or 4 considered "interested"). Participants with 2 or more treatment episodes in the past 5 years were considered treatment-experienced. We examined whether the number of past care episodes was associated with interest in iOAT.
Of 108 PWID, most participants were male (68.5%) and Hispanic (68.5%) with a mean age of 43 years (±10.8). Nearly all (98.1%) had severe OUD and had received past OUD care (96.3%), with the mean number of care episodes being 17.4 (SD, ±15.9). Most participants (59.8%) were treatment-experienced. Interest in iOAT with hydromorphone was high (64.8%), but there was no significant association between total past care episodes and expressing interest in iOAT (odds ratio, 1.02; 95% confidence interval, 0.99-1.05).
Participants were highly treatment-experienced, and iOAT interest was high regardless of prior OUD treatment. New OUD treatment options, such as iOAT with hydromorphone, would be welcomed by PWID whose OUD has not remitted with conventional treatment as well as other PWID.
注射用阿片类激动剂治疗（iOAT）是一种治疗阿片类使用障碍（OUD）的新方法，通常保留给有长期 OUD 且有注射毒品史的治疗经验丰富的人使用。本研究调查了注射毒品者（PWID）过去的 OUD 治疗史以及他们对氢吗啡酮 iOAT 的态度。
这项横断面研究招募了纽约市有 OUD 的注射毒品者。参与者自我报告过去的 OUD 护理期（解毒；门诊、住院或药物治疗；或互助小组）和当前对氢吗啡酮 iOAT 的兴趣（在 4 分制上评分，3 分或 4 分表示“感兴趣”）。在过去 5 年内有 2 次或更多治疗期的参与者被认为是有治疗经验的。我们研究了过去护理期的次数是否与对 iOAT 的兴趣有关。
在 108 名 PWID 中，大多数参与者为男性（68.5%）和西班牙裔（68.5%），平均年龄为 43 岁（±10.8）。几乎所有人（98.1%）都有严重的 OUD，并且接受过过去的 OUD 护理（96.3%），平均护理期数为 17.4 次（SD，±15.9）。大多数参与者（59.8%）有治疗经验。对氢吗啡酮 iOAT 的兴趣很高（64.8%），但过去护理总期数与表达对 iOAT 的兴趣之间没有显著关联（比值比，1.02；95%置信区间，0.99-1.05）。
参与者有高度的治疗经验，无论之前的 OUD 治疗如何，对 iOAT 的兴趣都很高。新的 OUD 治疗选择，如氢吗啡酮 iOAT，将受到那些常规治疗未缓解 OUD 的 PWID 以及其他 PWID 的欢迎。
